AN2 Therapeutics Inc. (ANTX) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
1800 EL CAMINO REAL, SUITE D MENLO PARK, CA 94027 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 3/31/2024 MRQ | 12/31/2023 | 12/31/2022 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments, including: | 107,295,000 | 99,300,000 | |||
| Cash and cash equivalents | 15,647,000 | 27,219,000 | |||
| Short-term investments | 91,648,000 | 68,840,000 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | 3,241,000 | ||||
| Other undisclosed current assets | 3,212,000 | (679,000) | |||
| Total current assets: | 110,507,000 | 98,621,000 | |||
| Noncurrent Assets | |||||
| Long-term investments and receivables | 27,194,000 | 3,219,000 | |||
| Long-term investments | 27,194,000 | 3,219,000 | |||
| Other noncurrent assets | 1,043,000 | 720,000 | |||
| Total noncurrent assets: | 28,237,000 | 3,939,000 | |||
| TOTAL ASSETS: | 138,744,000 | 102,560,000 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 9,357,000 | 4,959,000 | |||
| Accounts payable | 2,676,000 | 2,122,000 | |||
| Accrued liabilities | 6,681,000 | 2,837,000 | |||
| Other liabilities | 666,000 | ||||
| Other undisclosed current liabilities | 4,020,000 | 2,227,000 | |||
| Total current liabilities: | 14,043,000 | 7,186,000 | |||
| Noncurrent Liabilities | |||||
| Other undisclosed noncurrent liabilities | 2,000 | ||||
| Total noncurrent liabilities: | 2,000 | ||||
| Other undisclosed liabilities | |||||
| Total liabilities: | 14,043,000 | 7,188,000 | |||
| Equity | |||||
| Equity, attributable to parent | 124,701,000 | 95,372,000 | |||
| Additional paid in capital | 278,881,000 | 185,469,000 | |||
| Accumulated other comprehensive income (loss) | 275,000 | (374,000) | |||
| Accumulated deficit | (154,455,000) | (89,723,000) | |||
| Total equity: | 124,701,000 | 95,372,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 138,744,000 | 102,560,000 | |||
Income Statement (P&L) (USD)
| 3/31/2024 TTM | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Operating expenses | (69,635,000) | (42,262,000) | ||
| Operating loss: | (69,635,000) | (42,262,000) | ||
| Nonoperating income | 4,903,000 | 1,306,000 | ||
| Investment income, nonoperating | 1,351,000 | |||
| Other nonoperating income (expense) | 4,903,000 | (45,000) | ||
| Net loss attributable to parent: | (64,732,000) | (40,956,000) | ||
| Preferred stock dividends and other adjustments | (1,820,000) | |||
| Net loss available to common stockholders, diluted: | (64,732,000) | (42,776,000) | ||
Comprehensive Income (USD)
| 3/31/2024 TTM | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Net loss: | (64,732,000) | (40,956,000) | ||
| Comprehensive loss: | (64,732,000) | (40,956,000) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 649,000 | (347,000) | ||
| Comprehensive loss, net of tax, attributable to parent: | (64,083,000) | (41,303,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.